DREB1I Antibody

What is CREB1 and why is it a target for antibody research?

CREB1 (Cyclic AMP response element-binding protein 1) is a phosphorylation-dependent transcription factor that binds to the cAMP response element (CRE) in response to specific stimuli . It plays crucial roles in maintaining cellular homeostasis in both physiological and pathological conditions . The protein contains a basic leucine zipper (bZIP) DNA-binding domain, a dimerization domain, and 9 serine residues in a kinase inducible domain that can be phosphorylated by multiple kinases including CaMK II and IV, PKA, PKC, MSK, RSK, AKT, and MK2 . CREB1 is an important research target because it regulates cellular survival, proliferation, anti-inflammatory immune responses, and nervous system development . Additionally, increased CREB1 levels are associated with numerous cancers, including acute lymphoblastic leukemia, Hodgkin's lymphoma, and various solid tumors . Antibodies against CREB1 enable researchers to study its expression patterns, subcellular localization, and functional roles across diverse physiological and pathological contexts.

What are the recommended applications for CREB1 antibodies?

CREB1 antibodies have several validated research applications. Western blotting is a primary application, with the recommended usage of 1.0 μg/mL for detection of the 43 kD CREB1 protein in human and mouse cell lysates . Immunohistochemistry on formalin-fixed paraffin-embedded tissue sections is another verified application, with a suggested concentration range of 1.0-5.0 μg/ml . These applications allow researchers to investigate CREB1 expression across different cell types including B cells, endothelial cells, fibroblasts, granulocytes, macrophages, NK cells, and T cells . Each application requires optimization of antibody concentration for the specific experimental system. For optimal performance in western blotting, the antibody was purified by affinity chromatography and should be stored undiluted between 2°C and 8°C . The antibody solution contains phosphate-buffered solution at pH 7.2 with 0.09% sodium azide .

How do I validate the specificity of a CREB1 antibody for my research?

Validating CREB1 antibody specificity requires a multi-step approach. First, perform western blotting on positive control lysates known to express CREB1 (the antibody should detect a band at approximately 43 kD in human and mouse cell lysates) . Include negative controls where CREB1 is knocked down via siRNA. Cross-reactivity testing is essential - compare staining patterns across species if your research involves different model organisms (the antibody mentioned in the search results is verified for reactivity with human and mouse samples) . For immunohistochemistry applications, perform peptide competition assays where the antibody is pre-incubated with the immunizing peptide before staining; specific staining should be blocked by this competition. Additionally, compare results with alternative CREB1 antibodies targeting different epitopes. For all applications, titrate the antibody to determine optimal concentration - for western blotting, 1.0 μg/mL is suggested, while for IHC-P, a range of 1.0-5.0 μg/ml is recommended .

How can I optimize CREB1 antibody protocols for phosphorylation-specific detection?

Optimizing CREB1 antibody protocols for phosphorylation-specific detection requires consideration of CREB1's complex phosphorylation profile. Since CREB1 contains 9 serine residues in its kinase inducible domain that can be phosphorylated by multiple kinases (including CaMK II and IV, PKA, PKC, MSK, RSK, AKT, and MK2) , select phospho-specific antibodies that target the specific phosphorylation site of interest. For sample preparation, use comprehensive phosphatase inhibitor cocktails in lysis buffers to preserve phosphorylation states. Cell stimulation conditions should be tailored to the specific kinase pathway under investigation - for example, use forskolin or cAMP analogs for PKA-mediated phosphorylation. For western blotting, use BSA rather than milk for blocking (milk contains phosphoproteins that may interfere with detection), and consider using Phos-tag™ acrylamide gels to enhance separation of phosphorylated forms. Always run parallel samples with and without phosphatase treatment as controls, and include positive controls stimulated to induce the specific phosphorylation being studied.

What methodological approaches can detect changes in CREB1 expression across different disease models?

Detecting changes in CREB1 expression across disease models requires multiple complementary approaches. Since CREB1 dysregulation is associated with various pathological conditions including cancers and neurological disorders , quantitative analysis is essential. Western blotting using the purified anti-CREB1 antibody (1.0 μg/mL) provides quantitative assessment of protein levels in tissue or cell lysates . Immunohistochemistry on tissue sections (using 1.0-5.0 μg/ml concentration) allows visualization of expression patterns and cellular localization . For high-throughput screening, tissue microarrays combined with digital image analysis enable quantification across multiple samples. Flow cytometry with permeabilization protocols permits single-cell analysis of CREB1 expression in heterogeneous populations. For mechanistic insights, combine CREB1 staining with functional markers (proliferation, apoptosis) or cell-type specific markers. RNA-level analysis through qRT-PCR or RNA-seq provides complementary data on transcriptional regulation. For dynamic studies, longitudinal sampling in animal models allows tracking of CREB1 expression changes during disease progression or therapeutic intervention.

How do I investigate CREB1 interactions with its binding partners using antibody-based approaches?

Investigating CREB1 interactions requires specialized antibody-based techniques. CREB1 interacts with numerous proteins including CREBBP, CRTC2, EP300, CRTC1, JUN, AKT1, CAMK4, FOS, and various kinases . Co-immunoprecipitation (co-IP) is a primary method for studying these interactions - use cell lysis conditions that preserve protein complexes and select antibodies that don't interfere with interaction interfaces. To verify specificity, include controls such as IgG control IPs and competitive blocking with immunizing peptides. For detecting dynamic interactions that occur upon signaling events, treat cells with appropriate stimuli before lysis. Proximity ligation assay (PLA) allows visualization of protein interactions in situ by using two primary antibodies (anti-CREB1 and anti-binding partner) followed by oligonucleotide-linked secondary antibodies that generate a detectable signal when proteins are in close proximity. For mapping interaction domains, consider using different CREB1 antibodies recognizing specific regions in combination with truncated constructs of interaction partners.

What are the optimal sample preparation protocols for CREB1 detection in different cell types?

Optimal sample preparation for CREB1 detection varies by cell type and application. For adherent cells, direct lysis on the plate with ice-cold RIPA buffer containing protease inhibitors is recommended. For suspension cells (B cells, T cells, macrophages) , centrifuge to pellet cells before lysis. Since CREB1 is primarily nuclear , nuclear extraction protocols may provide enriched samples - use either differential centrifugation or commercial nuclear extraction kits. For phosphorylated CREB1 detection, add phosphatase inhibitors to all buffers. For western blotting, load 20-40 μg total protein per lane. For immunohistochemistry, tissue fixation with 4% paraformaldehyde is standard, though fixation time may need optimization for different tissue types. Antigen retrieval for formalin-fixed paraffin-embedded tissues typically requires heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 8.0). For immunofluorescence, 2-4% paraformaldehyde fixation for 10-15 minutes followed by permeabilization with 0.1-0.5% Triton X-100 is commonly effective.

How do I troubleshoot weak or non-specific signals when using CREB1 antibodies?

Troubleshooting signal issues with CREB1 antibodies requires systematic evaluation of multiple parameters. For weak signals, increase antibody concentration within the recommended range (1.0 μg/mL for western blotting, 1.0-5.0 μg/ml for IHC-P) , extend primary antibody incubation time, or optimize detection systems. Ensure your sample contains adequate CREB1 by using positive control lysates. For nuclear proteins like CREB1, verify your extraction method effectively isolates nuclear fractions. For non-specific signals, dilute the antibody further, optimize blocking conditions, or increase washing stringency. For western blotting, non-specific bands might be reduced by optimizing gel percentage, running time, or transfer conditions. Verify the expected molecular weight (43 kD for CREB1) and compare with positive control lysates. For IHC or IF applications, excessive background may be addressed by including peroxidase/phosphatase blocking steps, optimizing antigen retrieval, or using more stringent washing protocols. Always include appropriate controls: positive and negative control tissues/cells, isotype control antibodies, and for phospho-specific detection, samples treated with phosphatases.

What considerations are important when using CREB1 antibodies for immunoprecipitation studies?

Successful immunoprecipitation with CREB1 antibodies requires attention to several critical factors. First, antibody selection is paramount - the antibody must recognize native CREB1 conformation rather than just denatured epitopes. Cell lysis conditions must preserve protein structure and interactions - use non-denaturing buffers containing mild detergents like NP-40 or Triton X-100. Since CREB1 is primarily nuclear , nuclear extraction protocols may increase yield. Pre-clearing lysates with protein A/G beads before adding the CREB1 antibody reduces non-specific binding. The antibody-to-lysate ratio should be optimized through titration experiments. For co-immunoprecipitation studies investigating CREB1's numerous binding partners , crosslinking may be necessary to capture transient interactions. When analyzing phosphorylated CREB1, include phosphatase inhibitors in all buffers and maintain cold conditions throughout. Elution conditions should be optimized based on downstream applications - mild elution with peptide competition may preserve protein complexes for interaction studies, while harsher SDS-based elution maximizes recovery for western blotting. Always include appropriate controls: isotype-matched IgG, input lysate samples, and negative control lysates where CREB1 is depleted.

How can CREB1 antibodies be used to study its role in cancer progression?

CREB1 antibodies are valuable tools for studying its role in cancer progression. Increased CREB1 levels are associated with multiple cancers including acute lymphoblastic leukemia, Hodgkin's lymphoma, and various solid tumors (melanoma, hepatocellular, renal cell, ovarian, prostate, lung, gastric, esophageal, pancreatic, and breast tumors) . Immunohistochemistry using anti-CREB1 antibodies (1.0-5.0 μg/ml) on tumor tissue microarrays can establish correlations between CREB1 expression and clinical outcomes or tumor stages. Western blotting of tumor lysates versus adjacent normal tissue can quantify CREB1 upregulation, while phospho-specific antibodies can assess activation status. Chromatin immunoprecipitation followed by sequencing allows genome-wide mapping of CREB1 binding sites in cancer cells, revealing cancer-specific transcriptional programs. For functional studies, combine CREB1 antibody-based detection with cell proliferation assays, apoptosis detection, or migration assays following CREB1 inhibition. Co-immunoprecipitation with CREB1 antibodies can identify cancer-specific interaction partners. In xenograft models, immunofluorescence can monitor changes in expression during tumor progression or in response to therapy.

What role does CREB1 play in neurological disorders and how can antibodies help investigate this?

CREB1 serves as a neuroprotective factor in the nervous system , making it relevant to neurological disorder research. Antibody-based approaches can elucidate its role in these conditions. Immunohistochemistry with CREB1 antibodies on brain tissue sections from patients or animal models reveals expression patterns across different neural cell populations. Western blotting with phospho-specific antibodies against different CREB1 phosphorylation sites (particularly Ser133) can quantify activation levels in brain tissue samples or neuronal cultures. Immunofluorescence co-staining with CREB1 antibodies and neuronal or glial markers reveals cell type-specific expression patterns. For mechanistic studies, chromatin immunoprecipitation followed by sequencing identifies CREB1 target genes in neuronal cells, revealing regulatory networks affected in neurological disorders. In primary neuronal cultures, calcium imaging combined with CREB1 immunostaining links neuronal activity to CREB1 activation. For translational relevance, correlate CREB1 expression or phosphorylation with behavioral outcomes in animal models or with clinical parameters in human studies.

How do HLA-DRB1 alleles influence autoantibody responses, and what techniques can investigate this relationship?

HLA-DRB1 alleles significantly influence autoantibody responses in autoimmune diseases, with genetic variations in HLA-DRB1 being major contributors to seropositive rheumatoid arthritis (RA) . Specific alleles known as "shared epitope" alleles (from HLA-DRB1 groups *01, *04, and 10) are genetic risk factors for RA across different ethnic populations and are primarily associated with anti-citrullinated protein antibody (ACPA)-positive RA . Recent research has identified additional associations, with non-shared epitope alleles HLA-DRB109 and *15 showing significant associations with ACPA levels independent of ethnicity . These findings indicate previously overlooked roles for HLA locus in regulating autoantibody levels beyond the shared epitope-defined gene variants . Investigation techniques include statistical analysis of antibody levels as quantitative traits rather than categorical variables, integrating ELISA data with HLA genotyping, and applying regression models that account for confounding factors . Stratification approaches that isolate the effects of specific alleles by creating reference groups allow precise assessment of individual allele contributions to autoantibody responses .

How can deep learning approaches improve antibody specificity and sensitivity?

Deep learning approaches are transforming antibody development, as demonstrated in the "Lab-in-the-loop" paradigm for therapeutic antibody design . This approach integrates generative machine learning models, multi-task property predictors, active learning ranking and selection, and in vitro experimentation in a semi-autonomous, iterative optimization loop . By automating design of antibody variants, property prediction, ranking and selection of designs to assay, and ingestion of in vitro data, this system enables a holistic, end-to-end approach to antibody optimization . Applied to clinically relevant targets, this methodology has produced significantly improved binding variants, with the best binders reaching therapeutically relevant 100 pM affinity ranges . The combination of computational prediction with experimental validation creates a powerful feedback loop where each iteration improves model accuracy. For antibodies targeting complex proteins like CREB1, deep learning can analyze protein structure to identify optimal epitopes that maximize specificity and minimize cross-reactivity with related proteins.

What experimental design is optimal for validating CREB1 antibodies across multiple applications?

Optimal experimental design for comprehensive CREB1 antibody validation requires a multi-platform approach. Begin with western blotting validation using positive control lysates from cells known to express CREB1 (the antibody should detect a 43 kD band in human and mouse samples) alongside negative controls (CREB1 knockdown samples). Include titration experiments to determine optimal antibody concentration (recommended starting point: 1.0 μg/mL) . For immunohistochemistry validation, test the antibody on a tissue panel with known CREB1 expression patterns at various concentrations (1.0-5.0 μg/ml recommended range) , including positive and negative control tissues. Perform peptide competition assays to confirm specificity. For immunoprecipitation validation, compare the efficiency of immunoprecipitated CREB1 against input controls and IgG controls. Test reproducibility by performing experiments with different antibody lots and by independent researchers. Cross-validate with orthogonal methods - compare protein levels detected by the antibody with mRNA levels from qPCR or RNA-seq. For ChIP applications, validate by qPCR of known CREB1 target genes. Document all validation data completely, including images of entire western blots with molecular weight markers and all controls.